Salivary proteinase activity: A potential biomarker for preterm premature rupture of the membranes

Ramkumar Menon, J. Oliver McIntyre, Lynn M. Matrisian, Stephen J. Fortunato

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The objective of this study was to design a method to identify patients at risk for preterm premature rupture of the membranes using a simple assay of salivary proteinase activity. Study design: Saliva samples were collected from women in the following groups using Salivette: (1) nonpregnant control; (2) during the second trimester of pregnancy; (3) during active labor at term; (4) women with premature rupture of the membranes before preterm delivery; and (5) postpartum (within 3 hours after delivery at term). Total proteolytic activity in saliva samples was measured by fluorometry using the generic substrate DQ-gelatin in the presence of specific inhibitors to selectively detect matrix metalloproteinase activities. The concentrations of various matrix metalloproteinases in saliva samples were also measured by multiplex bead assay using the Luminex platform. Results: All saliva samples exhibited detectable matrix metalloproteinase activity. Salivary matrix metalloproteinase activity is low in nonpregnant females (0.27 ± 0.15) and increases in samples taken in the second trimester (0.5 ± 0.5) and at term during active labor (1.03 ± 1.2). Samples collected from women with premature rupture of the membranes before preterm delivery had the highest activity (2.5 ± 3.7) followed by postpartum after normal term delivery (2.1 ± 1.6). The matrix metalloproteinase activity was higher in premature rupture of the membranes before preterm delivery samples, compared with all other stages of pregnancy. Multiplex matrix metalloproteinase assay documented a significant increase in total matrix metalloproteinase-9 concentration in saliva from premature rupture of the membranes before preterm delivery, compared with any of the other groups. Similarly matrix metalloproteinase-9 activity was also significantly increased in premature rupture of the membranes before preterm delivery group, compared with all others. Conclusion: Herein we report a simple test to monitor proteolytic enzyme activity in saliva during pregnancy. The highest matrix metalloproteinase activity is seen in premature rupture of the membranes before preterm delivery and postpartum samples. Ongoing studies aim to further define salivary proteinase activity in patients at high risk for premature rupture of the membranes before preterm delivery and to evaluate its potential as a predictive test for premature rupture of the membranes before preterm delivery.

Original languageEnglish (US)
Pages (from-to)1609-1615
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume194
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Peptide Hydrolases
Matrix Metalloproteinases
Biomarkers
Saliva
Postpartum Period
Matrix Metalloproteinase 9
Second Pregnancy Trimester
Preterm Premature Rupture of the Membranes
Pregnancy
Fluorometry
Gelatin

Keywords

  • Biomarker
  • Matrix metalloproteinases
  • Prematurity
  • Preterm birth
  • Proteinase
  • Saliva

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Salivary proteinase activity : A potential biomarker for preterm premature rupture of the membranes. / Menon, Ramkumar; McIntyre, J. Oliver; Matrisian, Lynn M.; Fortunato, Stephen J.

In: American Journal of Obstetrics and Gynecology, Vol. 194, No. 6, 06.2006, p. 1609-1615.

Research output: Contribution to journalArticle

Menon, Ramkumar ; McIntyre, J. Oliver ; Matrisian, Lynn M. ; Fortunato, Stephen J. / Salivary proteinase activity : A potential biomarker for preterm premature rupture of the membranes. In: American Journal of Obstetrics and Gynecology. 2006 ; Vol. 194, No. 6. pp. 1609-1615.
@article{ec730be4f13745c385e908e988885abd,
title = "Salivary proteinase activity: A potential biomarker for preterm premature rupture of the membranes",
abstract = "Objective: The objective of this study was to design a method to identify patients at risk for preterm premature rupture of the membranes using a simple assay of salivary proteinase activity. Study design: Saliva samples were collected from women in the following groups using Salivette: (1) nonpregnant control; (2) during the second trimester of pregnancy; (3) during active labor at term; (4) women with premature rupture of the membranes before preterm delivery; and (5) postpartum (within 3 hours after delivery at term). Total proteolytic activity in saliva samples was measured by fluorometry using the generic substrate DQ-gelatin in the presence of specific inhibitors to selectively detect matrix metalloproteinase activities. The concentrations of various matrix metalloproteinases in saliva samples were also measured by multiplex bead assay using the Luminex platform. Results: All saliva samples exhibited detectable matrix metalloproteinase activity. Salivary matrix metalloproteinase activity is low in nonpregnant females (0.27 ± 0.15) and increases in samples taken in the second trimester (0.5 ± 0.5) and at term during active labor (1.03 ± 1.2). Samples collected from women with premature rupture of the membranes before preterm delivery had the highest activity (2.5 ± 3.7) followed by postpartum after normal term delivery (2.1 ± 1.6). The matrix metalloproteinase activity was higher in premature rupture of the membranes before preterm delivery samples, compared with all other stages of pregnancy. Multiplex matrix metalloproteinase assay documented a significant increase in total matrix metalloproteinase-9 concentration in saliva from premature rupture of the membranes before preterm delivery, compared with any of the other groups. Similarly matrix metalloproteinase-9 activity was also significantly increased in premature rupture of the membranes before preterm delivery group, compared with all others. Conclusion: Herein we report a simple test to monitor proteolytic enzyme activity in saliva during pregnancy. The highest matrix metalloproteinase activity is seen in premature rupture of the membranes before preterm delivery and postpartum samples. Ongoing studies aim to further define salivary proteinase activity in patients at high risk for premature rupture of the membranes before preterm delivery and to evaluate its potential as a predictive test for premature rupture of the membranes before preterm delivery.",
keywords = "Biomarker, Matrix metalloproteinases, Prematurity, Preterm birth, Proteinase, Saliva",
author = "Ramkumar Menon and McIntyre, {J. Oliver} and Matrisian, {Lynn M.} and Fortunato, {Stephen J.}",
year = "2006",
month = "6",
doi = "10.1016/j.ajog.2006.02.052",
language = "English (US)",
volume = "194",
pages = "1609--1615",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Salivary proteinase activity

T2 - A potential biomarker for preterm premature rupture of the membranes

AU - Menon, Ramkumar

AU - McIntyre, J. Oliver

AU - Matrisian, Lynn M.

AU - Fortunato, Stephen J.

PY - 2006/6

Y1 - 2006/6

N2 - Objective: The objective of this study was to design a method to identify patients at risk for preterm premature rupture of the membranes using a simple assay of salivary proteinase activity. Study design: Saliva samples were collected from women in the following groups using Salivette: (1) nonpregnant control; (2) during the second trimester of pregnancy; (3) during active labor at term; (4) women with premature rupture of the membranes before preterm delivery; and (5) postpartum (within 3 hours after delivery at term). Total proteolytic activity in saliva samples was measured by fluorometry using the generic substrate DQ-gelatin in the presence of specific inhibitors to selectively detect matrix metalloproteinase activities. The concentrations of various matrix metalloproteinases in saliva samples were also measured by multiplex bead assay using the Luminex platform. Results: All saliva samples exhibited detectable matrix metalloproteinase activity. Salivary matrix metalloproteinase activity is low in nonpregnant females (0.27 ± 0.15) and increases in samples taken in the second trimester (0.5 ± 0.5) and at term during active labor (1.03 ± 1.2). Samples collected from women with premature rupture of the membranes before preterm delivery had the highest activity (2.5 ± 3.7) followed by postpartum after normal term delivery (2.1 ± 1.6). The matrix metalloproteinase activity was higher in premature rupture of the membranes before preterm delivery samples, compared with all other stages of pregnancy. Multiplex matrix metalloproteinase assay documented a significant increase in total matrix metalloproteinase-9 concentration in saliva from premature rupture of the membranes before preterm delivery, compared with any of the other groups. Similarly matrix metalloproteinase-9 activity was also significantly increased in premature rupture of the membranes before preterm delivery group, compared with all others. Conclusion: Herein we report a simple test to monitor proteolytic enzyme activity in saliva during pregnancy. The highest matrix metalloproteinase activity is seen in premature rupture of the membranes before preterm delivery and postpartum samples. Ongoing studies aim to further define salivary proteinase activity in patients at high risk for premature rupture of the membranes before preterm delivery and to evaluate its potential as a predictive test for premature rupture of the membranes before preterm delivery.

AB - Objective: The objective of this study was to design a method to identify patients at risk for preterm premature rupture of the membranes using a simple assay of salivary proteinase activity. Study design: Saliva samples were collected from women in the following groups using Salivette: (1) nonpregnant control; (2) during the second trimester of pregnancy; (3) during active labor at term; (4) women with premature rupture of the membranes before preterm delivery; and (5) postpartum (within 3 hours after delivery at term). Total proteolytic activity in saliva samples was measured by fluorometry using the generic substrate DQ-gelatin in the presence of specific inhibitors to selectively detect matrix metalloproteinase activities. The concentrations of various matrix metalloproteinases in saliva samples were also measured by multiplex bead assay using the Luminex platform. Results: All saliva samples exhibited detectable matrix metalloproteinase activity. Salivary matrix metalloproteinase activity is low in nonpregnant females (0.27 ± 0.15) and increases in samples taken in the second trimester (0.5 ± 0.5) and at term during active labor (1.03 ± 1.2). Samples collected from women with premature rupture of the membranes before preterm delivery had the highest activity (2.5 ± 3.7) followed by postpartum after normal term delivery (2.1 ± 1.6). The matrix metalloproteinase activity was higher in premature rupture of the membranes before preterm delivery samples, compared with all other stages of pregnancy. Multiplex matrix metalloproteinase assay documented a significant increase in total matrix metalloproteinase-9 concentration in saliva from premature rupture of the membranes before preterm delivery, compared with any of the other groups. Similarly matrix metalloproteinase-9 activity was also significantly increased in premature rupture of the membranes before preterm delivery group, compared with all others. Conclusion: Herein we report a simple test to monitor proteolytic enzyme activity in saliva during pregnancy. The highest matrix metalloproteinase activity is seen in premature rupture of the membranes before preterm delivery and postpartum samples. Ongoing studies aim to further define salivary proteinase activity in patients at high risk for premature rupture of the membranes before preterm delivery and to evaluate its potential as a predictive test for premature rupture of the membranes before preterm delivery.

KW - Biomarker

KW - Matrix metalloproteinases

KW - Prematurity

KW - Preterm birth

KW - Proteinase

KW - Saliva

UR - http://www.scopus.com/inward/record.url?scp=33646770958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646770958&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2006.02.052

DO - 10.1016/j.ajog.2006.02.052

M3 - Article

C2 - 16731078

AN - SCOPUS:33646770958

VL - 194

SP - 1609

EP - 1615

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -